Advances in diagnosis and therapy of neuroendocrine tumors

Expert Review of Anticancer Therapy

Volumn 1, Issue 3, 2001, Pages 371-381

  Bajetta, Emilio ^a   Procopio, Giuseppe ^a   Buzzoni, Roberto ^a   Catena, Laura ^a   Ferrari, Leonardo ^a   Del Vecchio, Michele ^a  

^a Medical Oncology Unit B   (Italy)

Author keywords

Antracyclines; Dacarbazine; Etoposide; Fluoropyrimidines; Interferon; Lanreotide; Neuroendocrine tumors; Octreotide; Platin Analogs

Indexed keywords

(3 IODOBENZYL)GUANIDINE; ALPHA INTERFERON; ANGIOPEPTIN; CALCIUM CHANNEL BLOCKING AGENT; CAPECITABINE; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; INTERLEUKIN 12; IODINE 131; IRINOTECAN; MITOMYCIN C; MONOCLONAL ANTIBODY; OCTREOTIDE; OXALIPLATIN; PENTETREOTIDE; PENTETREOTIDE IN 111; SOMATOSTATIN DERIVATIVE; STREPTOZOCIN; TEMOZOLOMIDE; THALIDOMIDE; VINCRISTINE; YTTERBIUM;

ADVANCED CANCER; BRAIN SCINTISCANNING; CANCER GRADING; CANCER GROWTH; CARCINOID SYNDROME; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG COST; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; FLU LIKE SYNDROME; GALLBLADDER DISEASE; GALLSTONE; GENETIC HETEROGENEITY; HISTOPATHOLOGY; HUMAN; LIVER DISEASE; METASTASIS; NEUROENDOCRINE TUMOR; POSITRON EMISSION TOMOGRAPHY; REVIEW; THROMBOCYTOPENIA; THYROID MEDULLARY CARCINOMA; TUMOR DIFFERENTIATION; VIRAL GENE DELIVERY SYSTEM;

EID: 0035559617     PISSN: 14737140     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737140.1.3.371     Document Type: Review

References (81)

1. An analysis of 8305 cases of carcinoid tumors
2. Carcinoid tumors: An analysis of 2837 cases
3. Review: Carcinoid of the pancreas. Clinical characteristics and morphological features
4. ECL tumor and poorly differentiated endocrine carcinoma of the stomach: Prognostic evaluation by pathological analysis
5. Neuroendocrine neoplasia of the lung: Key references
6. Neuroendocrine tumors of the lung with proposed criteria for large-cell neuroendocrine carcinoma. An ultrastructural, immuno-histochemical and flow cytometric study of 35 cases
7. The diffuse neuroendocrine system and the APUD concept: Related 'endocrine' peptides in brain, intestine, pituitary, placenta and human cutaneous glands
8. Genesis of neuroendocrine system
9. Positional cloning of the gene for multiple endocrine neoplasia-type 1
10. Menin, the product of the MEN1 gene, is a nuclear protein
11. Multiple endocrine neoplasia Type 1: Current concepts in diagnosis and management
12. Multiple endocrine neoplasia Type 1
13. Multiple endocrine neoplasia Type 1: Clinical and genetic features
14. Multiple neoplasia Type 1: Clinical and genetic topics
15. Genetic testing in the diagnosis and management of multiple endocrine neoplasia Type I
16. The association of pheochromocytoma with carcinoma of the thyroid gland
17. Genotype-phenotype correlation in multiple endocrine neoplasia Type 2: Report of the international RET Mutation Consortium
18. Medullary carcinoma of the thyroid gland
19. Multiple endocrine neoplasia Type 2: Recent progress in diagnosis and management
20. Identification of multiple endocrine neoplasia, Type 2 gene carriers using linkage analysis and analysis of the RET protooncogene
21. Laboratory tests for neuroendocrine tumors
22. Tumor markers in neuroendocrine tumors
23. Serum neuron specific enolase in children's cancer
24. Neuron specific enolase: A useful diagnostic serum marker for small cell carcinoma of the lung
25. Evaluation of γ-enolase as a tumor marker for lung cancer
26. Serum chromogranin A in the diagnosis and follow-up of neuroendocrine tumors of the gastroenteropancreatic tract
27. Chromogranins - New sensitive markers for neuroendocrine tumors
28. Chromogranin A, neuron specific enolase, carcinoembryonic antigen and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors
29. Carcinoid tumors: Analysis of prognostic factors and survival in 301 patients from a referral center
30. Peptide hormones as tumor markers in neuroendocrine gastrointestinal tumors
31. Serotonin, catecholamines, histamine and their metabolites in urine, platelets and tumor tissue of patients with carcinoid tumors
32. The malignant carcinoid syndrome
33. State of the art and future prospects in the management of neuroendocrine tumors
34. Localization of gastroenteropancreatic tumors by angiography
35. Role of selective angiography in the management of patients with Zollinger-Ellison syndrome
36. Usefulness of selective arterial secretin injection test for localization of gastrinoma in the Zollinger-Ellison syndrome
37. Localization of insulinomas to regions of the pancreas by intra-arterial stimulation with calcium
38. Extrapancreatic gastrinoma localization; value of arterial phase helical CT with water as an oral contrast agent
39. Case report; multiple duodenal gastrinomas demonstrated with spiral CT
40. Endoscopic ultrasound is highly accurate and directs management in patients with neuroendocrine tumors of the pancreas
41. Radiolabelled metaiodobenzylguanidine in the diagnosis of neural crest tumors
42. Current concepts on the diagnostic use of MIBG in children
43. Results and potential of somatostatin receptor imaging in gastroenteropancreatic tract tumors
44. New radiopharmaceuticals for receptor scintigraphy and radionuclide therapy
45. In vivo study of amino acid distribution and metabolism in pituitary adenomas using positron emission tomography with 11C-D-methionine and 11C-L-methionine
46. Pancreatic neuroendocrine tumors: Diagnosis with PET
47. Neuroendocrine tumor imaging: Can 18F-fluorodeoxyglucose positron emission tomography detect tumors with poor prognosis and aggressive behavior?
48. Use of PET in neuroendocrine tumors. In vivo applications and in vitro studies
49. The new technology of combined transmission and emission tomography in evaluation of endocrine neoplasms
50. Intraoperative use of gamma-detecting probes to localize neuroendocrine tumors
51. Surgical treatment of midgut carcinoid tumors
52. Treatment of hepatic metastases from gastroenteropancreatic neuroendocrine tumors: Role of liver transplantation
53. Haepatic arterial chemoembolization in the management of advanced digestive endocrine tumors
54. Chemoembolization of haepatic metastases from intestinal neuroendocrine tumors
55. Cryoablation, percutaneous alcohol injection and radiofrequency ablation for treatment of neuroendocrine liver metastases
56. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variance of these neoplasms
57. Treatment of poorly differentiated neuroendocrine tumors with etoposide and cisplatin
58. Streptozotocin plus fluorouracil versus doxorubicin therapy for metastatic carcinoid tumor
59. Doxorubicin, streptozotocin and 5-fluorouracil chemotherapy for patients with metastatic islet-cell carcinoma
60. The treatment of advanced neuroendocrine tumors: Activity of a combination chemotherapy
61. A Phase II trial of dacarbazine, fluorouracil and epirubicin in patients with neuroendocrine tumors. A study by the Italian Trials in Medical Oncology (I.T.M.O.) Group
62. 5-fluorouracil, dacarbazine and epirubicin in the treatment of patients with neuroendocrine tumors
63. Malignant pheochromocytoma: Effective treatment with a combination of cyclophosphamide, vincristine and dacarbazine
64. Chemotherapy in neuroendocrine/Merkel cell's carcinoma of the skin: Case series and review of 204 cases
65. Carcinoid tumors: Current concepts in diagnosis and treatment
66. Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors
67. Mini review: The somatostatin receptor family
68. Octreotide
69. Octreotide acetate long-acting formulation versus open-label sc. octreotide acetate in malignant carcinoid syndrome
70. Treatment of carcinoid syndrome
71. Octreotide acetate long-acting release in patients with metastatic neuroendocrine tumors pretreated with lanreotide
72. Treatment of carcinoid syndrome with recombinant interferon alpha-2a
73. Treatment of metastatic carcinoid and other neuroendocrine tumors with recombinant interferon alpha-2a
74. Combination therapy with octreotide and alpha-interferon
75. Expression of p68 protein kinase and its prognostic significance during IFN-alpha therapy in patients with carcinoid tumors
76. 131I-metaiodobenzylguanidine (mIBG) in treatment of neuroendocrine tumors (Experience of National Cancer Institute of Milan)
77. Chemotherapy of metastatic carcinoid and islet cell tumors
78. Radiolabeled monoclonal antibodies
79. Yttrium-90 labelled somatostatin analogue for cancer treatment
80. Genetic immunotherapy of established tumors with adenoviral vectors transducing murine interleukin-12 (mIL 12) subunits in a rat medullary thyroid carcinoma model